Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast by 2035

August 07 20:04 2020
Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast by 2035

DelveInsight Business Research LLP
DelveInsight’s ‘Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast by 2035’ report delivers an in-depth understanding of the Neoantigen based Personalized Cancer therapeutic Vaccines and the Neoantigen-based personalized cancer therapeutic vaccines emerging market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Cancer therapeutic Vaccines use weakened or killed viruses, bacteria, or other germs to start an immune response in the body. These vaccines are designed to work in a similar manner, teaching the immune system to recognize, attack and destroy cancer cells.

 

  • Neoantigen-based Personalized Cancer therapeutic Vaccines allows the immune system to recognize cancer cells as foreign, and therefore, get the immune system to attack the cancer cells.

 

  • Neoantigen-based cancer vaccines also target several other indications like:-
  • Bone Cancer
  • Pancreatic Ductal Adenocarcinoma
  • Colorectal Cancer
  • Urothelial Carcinoma
  • Cutaneous Melanoma
  • Renal Cell Carcinoma and others.

 

Neoantigen-based Personalized Cancer therapeutic Vaccines pipeline

Drugs:-

  • Vigil
  • Tedopi (OSE2101)
  • Hepko-V5
  • GRANITE (GRT-C901) + SLATE (GRT-R902)
  • GEN-009
  • TG01 Vaccine
  • iNeo-Vac-P01
  • NEO-PV-01

And many others

Key Players:-

  • Gradalis
  • OSE Immunotherapeutics
  • Immunitor
  • Gristone Oncology
  • Genocea
  • Targovax
  • Hangzhou Neoantigen Therapeutics
  • Neon Therapeutics

And many others

 

Scope of the Report 

  • The report covers the descriptive overview of Neoantigen-based Personalized Cancer therapeutic Vaccines.
  • Comprehensive insight has been provided into the Neoantigen-based Personalized Cancer therapeutic Vaccines for several cancer indications and treatment in the 7MM.
  • Additionally, an all-inclusive account of emerging vaccines for Neoantigen-based Personalized Cancer therapeutic Platform are provided, along with the assessment of new therapies, which will have an impact on the market.
  • A detailed review of Neoantigen-based Personalized Cancer therapeutic Vaccines market; forecasted is included in the report, covering vaccine outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Neoantigen-based Personalized Cancer Therapeutic Vaccines market.

Request for sample pages

Table of contents

1. Key Insights

2. Executive Summary of Neoantigen-based Personalized Cancer therapeutic Vaccines

3. Competitive Intelligence Analysis for Neoantigen-based Personalized Cancer therapeutic Vaccines

4. Neoantigen-based Personalized Cancer therapeutic Vaccines: Market Overview at a Glance

4.1. Neoantigen-based Personalized Cancer therapeutic Vaccines-Region Wise Total Market Share (%) Distribution by 2035

4.2. Neoantigen-based Personalized Cancer therapeutic Vaccines-Indication Wise Total Market Share (%) Distribution by 2035

5. Neoantigen-based Personalized Cancer therapeutic Vaccines

5.1. Introduction

5.1.1. Tumor neoantigens: from basic research to clinical applications

5.1.2. Historical overview in the understanding of tumor neoantigens

5.1.3. Neoantigens-directed immunoediting and immune escape

5.1.4. Overview of Preclinical and clinical neoantigen vaccine-based studies

5.1.4.1. Neoantigen-based adoptive T cell transfer

5.1.4.2. Neoantigen-based cancer vaccines

5.1.4.3. Combination of neoantigen vaccine with other therapies

5.1.4.3.1. Biomarker for immune checkpoint inhibitors

5.1.4.3.2. Resistance mechanism for immune checkpoint inhibitors

5.1.5. Identification and prediction of neoantigens

5.1.6. Principle of neoantigen vaccines

5.1.7. Clinical progress

5.1.8. Pros and Cons

6. Unmet Needs

7. Emerging Therapies

7.1. Key Cross Competition

7.2. Tedopi (OSE2101): OSE Immunotherapeutics

7.2.1. Product Description

7.2.2. Other Developmental Activities

7.2.3. Clinical Development

7.2.4. Safety and Efficacy

7.2.5. Product Profile

7.3. GRANITE (GRT-C901) + SLATE (GRT-R902): Gritstone Oncology

7.3.1. Product Description

7.3.2. Other Developmental Activities

7.3.3. Clinical Development

7.3.4. Safety and Efficacy

7.3.5. Product Profile

7.4. GEN-009 Adjuvanted Vaccine: Genocea Biosciences

7.4.1. Product Description

7.4.2. Other Developmental Activities

7.4.3. Clinical Development

7.4.4. Safety and Efficacy

7.4.5. Product Profile

7.5. TG01 Vaccine: Targovax

7.5.1. Product Description

7.5.2. Other Developmental Activities

7.5.3. Clinical Development

7.5.4. Safety and Efficacy

7.5.5. Product Profile

7.6. iNeo-Vac-P01: Hangzhou Neoantigen Therapeutics

7.6.1. Product Description

7.6.2. Other Developmental Activities

7.6.3. Clinical Development

7.6.4. Safety and Efficacy

7.6.5. Product Profile

7.7. NEO-PV-01: Neon Therapeutics

7.7.1. Product Description

7.7.2. Other Developmental Activities

7.7.3. Clinical Development

7.7.4. Safety and Efficacy

7.7.5. Product Profile

List to be continued in report…

8. Neoantigen-based Personalized Cancer therapeutic Vaccines: Seven Major Market Analysis

8.1. Key Findings

8.2. Neoantigen-based Personalized Cancer therapeutic Vaccines Market Size in 7MM

9. 7MM: Market Outlook

9.1. United States: Market Size

9.1.1. Neoantigen-based Personalized Cancer therapeutic Vaccines Total Market Size in the United States

9.1.2. Neoantigen-based Personalized Cancer therapeutic Vaccines Market Size by Therapies in the United States

9.2. EU-5 countries: Market Size and Outlook

9.2.1. Neoantigen-based Personalized Cancer therapeutic Vaccines Total Market Size in EU5 Countries

9.2.2. Neoantigen-based Personalized Cancer therapeutic Vaccines Market Size by Therapies in EU5 Countries

9.3. Japan Market Outlook

9.3.1. Neoantigen-based Personalized Cancer therapeutic Vaccines Total Market Size in Japan

9.3.2. Neoantigen-based Personalized Cancer therapeutic Vaccines Market Size by Therapies in Japan

10. Attribute analysis

11. KOL Views

12. Market Drivers

13. Market Barriers

14. Future Outlook

15. Appendix

15.1. Bibliography

15.2. Report Methodology

16. DelveInsight Capabilities

17. Disclaimer

18. About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/